This article is more than 5 years old. Information may no longer be current.
Immunogenicity to Remicade, biosimilar similar in patients with RA, AS
Click Here to Manage Email Alerts
Patients with rheumatoid arthritis and ankylosing spondylitis responded with a similar immunogenicity profile to Remicade and the Remicade biosimilar, Remsima, but other differences were observed between the two patient groups, according to recently presented research.
A group of 602 patients with rheumatoid arthritis (RA) enrolled in the PLANETRA study and 250 patients with ankylosing spondylitis (AS) enrolled in the PLANETAS study were retrospectively analyzed. Patients in each group were randomized to receive either 3 mg/kg or 5 mg/kg of either Remicade (infliximab, Janssen) or Remsima (CT-P13, Celltrion). Patients were assessed for the presence of anti-drug antibodies (ADA) at weeks 14, 30 and 54. Logistic regression analysis was conducted and adjusted for age, sex, race, and methotrexate or glucocorticoid use.
The results showed that the overall immunogenicity profile was similar between patients assigned to treatment with CT-P13 and infliximab; however, in patients with RA, age alone was shown to strongly impact ADA-positive status in both drug treatment groups. No association was seen in patients with AS in either drug treatment group.
“On the basis of similar immunogenicity between CT-P13 and infliximab in AS and RA patients, we only found age as an influencing factor in patients with RA,” the researchers wrote. “This finding may be related to the immunosenecence in the elderly.” – by Shirley Pulawski
Reference:
Braun J, et al. Paper #FRI0119. Presented at: European League Against Rheumatism Annual European Congress of Rheumatology; June 10-13, 2015; Rome.
Disclosures: Braun reports receiving grant/research support from Celltrion, for whom he is also on the speakers bureau and is a consultant. Please see the full study for a list of all other authors’ relevant financial disclosures.